Cocrystal Pharma (NASDAQ: COCP) issues Q3 2025 results press release

Rhea-AI Filing Summary

Cocrystal Pharma, Inc. filed a current report to share that it has released its financial results for the fiscal quarter ended September 30, 2025 and provided business updates. The company issued a press release on November 14, 2025 detailing these quarterly results and updates, and attached that release as Exhibit 99.1.

The report specifies that the earnings information under Item 2.02 and in Exhibit 99.1 is being furnished rather than filed, meaning it is not subject to certain liability provisions of the Exchange Act and is not automatically incorporated into other securities law filings unless expressly stated.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001412486 0001412486 2025-11-14 2025-11-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 14, 2025

Cocrystal Pharma, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-38418		35-2528215
(State or other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

19805 N. Creek Parkway Bothell, WA		98011
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (877) 262-7123

(Former name or former address, if changed since last report.): n/a

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		COCP		The Nasdaq Stock Market, LLC (The Nasdaq Capital Market)

Item 2.02 Results of Operations and Financial Condition

On November 14, 2025, Cocrystal Pharma, Inc. (the “Company”) issued a press release announcing its results of operations for the fiscal quarter ended September 30, 2025 and providing certain business updates. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02, and Exhibit 99.1 attached hereto, shall not be deemed “filed” for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934, as amended. Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, the information contained in this Item 2.02 and Exhibit 99.1 hereto shall not be incorporated by reference into any Company filing, whether made before or after the date hereof, regardless of any general incorporation language in such filing

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit		Description
99.1		Press Release dated November 14, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Cocrystal Pharma, Inc.
Date: November 14, 2025	By:	/s/ James Martin
	Name:	James Martin
	Title:	Co-Chief Executive Officer and Chief Financial Officer

FAQ

What did Cocrystal Pharma (COCP) report in this 8-K?

Cocrystal Pharma reported that it issued a press release announcing its results of operations for the fiscal quarter ended September 30, 2025 and provided certain business updates.

Which period’s results does Cocrystal Pharma (COCP) discuss?

The company’s press release covers its results of operations for the fiscal quarter ended September 30, 2025.

How did Cocrystal Pharma (COCP) provide its Q3 2025 results to investors?

The company provided its Q3 2025 results and business updates through a press release dated November 14, 2025, which is included as Exhibit 99.1.

Is the Cocrystal Pharma (COCP) earnings information considered filed with the SEC?

No. The information in Item 2.02 and Exhibit 99.1 is furnished, not filed, and is not subject to Section 18 liability unless expressly incorporated into another filing.

What exhibits are included with this Cocrystal Pharma (COCP) 8-K?

The 8-K includes Exhibit 99.1, the press release dated November 14, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

Who signed the Cocrystal Pharma (COCP) 8-K report?

The report was signed on behalf of Cocrystal Pharma, Inc. by James Martin, Co-Chief Executive Officer and Chief Financial Officer.